Clinical Trials

Amyndas’ lead compound AMY-101 is currently in two clinical trials:
  • Periodontal disease: A Phase 2a Clinical Trial to Assess the Safety and Efficacy of C3 Inhibitor AMY-101, in Adults with gingivitis, is currently ongoing (ClinicalTrials.gov Identifier: NCT03694444).
  • COVID-19: A Clinical Trial to Assess the Safety and Efficacy of C3 Inhibitor, AMY-101, in patients with Acute Respiratory Distress Syndrome (ARDS) due to SARS-CoV-2 infection (ClinicalTrials.gov Identifier: NCT04395456).
Additional phase II clinical trials of AMY-101 in priority indications are currently planned.